Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala.
Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala.
J Vasc Surg. 2019 Aug;70(2):539-546. doi: 10.1016/j.jvs.2018.07.089. Epub 2019 Feb 2.
Statin use is recommended in all patients with peripheral arterial disease (PAD) owing to its morbidity and mortality benefits. However, the effect of statin use on limb salvage in patients with PAD after intervention is unclear. We examined the effect of statin use on limb salvage and survival among patients with PAD undergoing surgical or endovascular intervention.
A total of 488 patients with PAD were identified who underwent surgical (n = 297) or endovascular (n = 191) intervention between 2009 and 2010. Information was collected from electronic medical records and the Social Security Death Index. Predictors of ongoing statin use were identified first by univariate analysis and then via multivariable logistic regression. Survival and freedom from amputation were identified using Kaplan-Meier plots and adjusted hazard ratios by Cox regression.
Of the 488 patients with PAD with intervention, 39% were non-whites, 44% were females, 41% received statins, 56% received antiplatelets, 26% received oral anticoagulants, 9% required a major amputation, and 11% died during follow-up of up to 88 months. Statin users were more often male (P = .03), white (P = .03), smokers (P < .01), and had higher comorbidities such as coronary artery disease (P < .01), hypertension (P < .01), and diabetes (P < .01). Antiplatelet use was not associated with limb salvage (P = .13), but did improve survival (P < .01). Dual antiplatelet therapy did not show any benefit over monotherapy for limb salvage (P = .4) or survival (P = .3). Statin use was associated with improved survival (P = .04), and improved limb salvage (hazard ratio, 0.3; 95% confidence interval, 0.1-0.7) after adjusting for severity of disease, traditional risk factors, and concurrent antiplatelet use.
Statin use in patients with PAD with interventions was associated with improved limb salvage and survival. Despite existing guidelines, statin therapy was low in our PAD population, and efforts are ongoing to increase their use across the health care system.
由于他汀类药物具有降低发病率和死亡率的益处,因此建议所有外周动脉疾病(PAD)患者使用。但是,他汀类药物对 PAD 患者介入治疗后肢体存活的影响尚不清楚。我们研究了他汀类药物在接受手术或血管内治疗的 PAD 患者中的肢体存活和生存的影响。
共纳入 2009 年至 2010 年期间接受手术(n=297)或血管内(n=191)干预的 488 例 PAD 患者。信息来自电子病历和社会安全死亡索引。首先通过单变量分析确定正在使用他汀类药物的预测因素,然后通过多变量逻辑回归确定。使用 Kaplan-Meier 图确定生存和免于截肢,并用 Cox 回归调整危险比。
在接受介入治疗的 488 例 PAD 患者中,39%为非白人,44%为女性,41%接受他汀类药物治疗,56%接受抗血小板治疗,26%接受口服抗凝剂治疗,9%需要进行大截肢,11%在长达 88 个月的随访期间死亡。与未使用者相比,他汀类药物使用者更多为男性(P=0.03),白人(P=0.03),吸烟者(P<0.01),且合并症更多,例如冠状动脉疾病(P<0.01),高血压(P<0.01)和糖尿病(P<0.01)。抗血小板治疗与肢体存活无关(P=0.13),但可改善生存(P<0.01)。双联抗血小板治疗在改善肢体存活(P=0.4)或生存(P=0.3)方面并不优于单药治疗。调整疾病严重程度,传统危险因素和同时使用抗血小板药物后,他汀类药物的使用与改善生存(P=0.04)和改善肢体存活(危险比,0.3;95%置信区间,0.1-0.7)相关。
在接受介入治疗的 PAD 患者中使用他汀类药物与改善肢体存活和生存有关。尽管存在指南,但我们的 PAD 人群中他汀类药物的使用率仍然较低,正在努力在整个医疗保健系统中增加其使用。